Updated results of a phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.

被引：1
|
作者：
Han, Boram
Kim, Hyeong Su
Choi, Dae Ro
Shim, Byoung Yong
Lee, Kyung Hee
Kim, Jin Won
Kim, Jung Han
Kim, Jung Hoon
Kim, Ho Young
Song, Hunho
Park, Choong Kee
Moon, Sung Hoon
Kim, Jong Hyeok
Jeon, Jang Yong
Lee, Jung Woo
Zang, Dae Young
机构：
[1] Hallym Univ, Med Ctr, Anyang, South Korea
[2] Hallym Univ, Med Ctr, Coll Med, Seoul, South Korea
[3] Hallym Univ, Chuncheon Sacred Heart Hosp, Chunchon, South Korea
[4] Cathol Univ Kore, St Vincents Hosp, Seoul, South Korea
[5] Yeungnam Univ Hosp, Dept Hemato Oncol, Daegu, South Korea
[6] Seoul Natl Univ Bundang Hosp, Dept Internal Med, Seoul, South Korea
[7] Hallym Univ, Coll Med, Med Ctr, Dept Internal Med, Anyang, South Korea
[8] Hallym Univ, Chuncheon Sacred Heart Hosp, Div Hematol Oncol, Dept Internal Med, Chunchon, South Korea
[9] Hallym Univ, Kang Dong Sacred Heart Hosp, Med Ctr, Seoul, South Korea
[10] Hallym Univ, Med Ctr, Anyang, South Korea
[11] Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Anyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15778
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15778
引用
下载
收藏
页数：6
相关论文
共 50 条
  • [21] A Phase 1 Study of Gemcitabine and S-1 Concurrent Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
    Matsumura, Yuji
    Suyama, Masafumi
    Sai, Jinkan
    Kubokawa, Yoshihiro
    Kamiya, Takayoshi
    Watanabe, Sumio
    PANCREAS, 2011, 40 (05) : 799 - 800
  • [22] Updated results of the GEST study: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer in Japan and Taiwan
    Fukutomi, Akira
    Okusaka, Takuji
    Sugimori, Kazuya
    Ueno, Hideki
    Ioka, Tatsuya
    Ohkawa, Shinichi
    Boku, Narikazu
    Yamao, Kenji
    Mizumoto, Kazuhiro
    Furuse, Junji
    Funakoshi, Akihiro
    Hatori, Takashi
    Yamaguchi, Taketo
    Egawa, Shinichi
    Sato, Atsushi
    Ohashi, Yasuo
    Cheng, Ann-Lii
    Tanaka, Masao
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer.
    Fang, Weijia
    Zhao, Peng
    Zheng, Yi
    Jiang, Weiqin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [24] A phase II multicentric trial of combined chemotherapy with gemcitabine plus S-1 in patients with advanced pancreatic cancer
    Ohkawa, S.
    Amano, A.
    Ueno, M.
    Miyakawa, K.
    Sugimori, K.
    Tanaka, K.
    Kida, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer
    Saito, Kei
    Isayama, Hiroyuki
    Nakai, Yousuke
    Takahara, Naminatsu
    Ishigaki, Kazunaga
    Takeda, Tsuyoshi
    Hakuta, Ryunosuke
    Saito, Tomotaka
    Uchino, Rie
    Kishikawa, Takahiro
    Hamada, Tsuyoshi
    Mizuno, Suguru
    Sasaki, Takashi
    Kogure, Hirofumi
    Matsubara, Saburo
    Yamamoto, Natsuyo
    Ijichi, Hideaki
    Tateishi, Keisuke
    Tada, Minoru
    Koike, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (02) : 338 - 344
  • [26] A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer
    Gomez-Martin, C.
    Camara, J. C.
    Cortes, H.
    Jara, C.
    Gravalos, C.
    Rubio, B.
    Amador, M. L.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer
    Kei Saito
    Hiroyuki Isayama
    Yousuke Nakai
    Naminatsu Takahara
    Kazunaga Ishigaki
    Tsuyoshi Takeda
    Ryunosuke Hakuta
    Tomotaka Saito
    Rie Uchino
    Takahiro Kishikawa
    Tsuyoshi Hamada
    Suguru Mizuno
    Takashi Sasaki
    Hirofumi Kogure
    Saburo Matsubara
    Natsuyo Yamamoto
    Hideaki Ijichi
    Keisuke Tateishi
    Minoru Tada
    Kazuhiko Koike
    Investigational New Drugs, 2019, 37 : 338 - 344
  • [28] Phase I/II study of gemcitabine plus S-1 with concurrent radiotherapy in patients of unresectable locally advanced pancreatic cancer
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Ishida, Nobuko
    Sueyoshi, Hironari
    Takada, Ryoji
    Yamai, Takuo
    Fukutake, Nobuyasu
    Ashida, Reiko
    Akita, Hirofumi
    Takahashi, Hidenori
    Kawaguchi, Yoshifumi
    Konishi, Koji
    Teshima, Teruki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [29] Final results of a phase II study of S-1 in patients with metastatic pancreatic cancer
    Funakoshi, A.
    Okusaka, T.
    Furuse, J.
    Boku, N.
    Yamao, K.
    Ohkawa, S.
    Saito, H.
    PANCREAS, 2006, 33 (04) : 462 - 462
  • [30] A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
    Ueno, M.
    Okusaka, T.
    Omuro, Y.
    Isayama, H.
    Fukutomi, A.
    Ikeda, M.
    Mizuno, N.
    Fukuzawa, K.
    Furukawa, M.
    Iguchi, H.
    Sugimori, K.
    Furuse, J.
    Shimada, K.
    Ioka, T.
    Nakamori, S.
    Baba, H.
    Komatsu, Y.
    Takeuchi, M.
    Hyodo, I.
    Boku, N.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 502 - 508
12345